迈威生物-U
(688062)
| 流通市值：70.34亿 | | | 总市值：153.90亿 |
| 流通股本：2.04亿 | | | 总股本：4.47亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,485,557,756.67 | 1,528,288,139.07 | 1,441,846,861.37 | 1,391,373,811.4 |
| 交易性金融资产 | 3,520,910.33 | - | 40,088,666.66 | - |
| 应收票据及应收账款 | 127,521,747.74 | 99,788,994.37 | 57,294,132.08 | 56,939,746.26 |
| 应收账款 | 127,521,747.74 | 99,788,994.37 | 57,294,132.08 | 56,939,746.26 |
| 预付款项 | 32,817,858.25 | 21,429,572.99 | 18,865,826.53 | 61,412,594.73 |
| 其他应收款合计 | 126,108,113.21 | 123,297,618.62 | 127,379,534.26 | 106,194,953.24 |
| 存货 | 197,923,019.95 | 187,896,531.45 | 198,560,783.7 | 210,839,836.85 |
| 其他流动资产 | 139,267,580.14 | 77,904,018.39 | 60,988,585.94 | 53,925,020.4 |
| 流动资产合计 | 2,112,716,986.29 | 2,038,604,874.89 | 1,945,024,390.54 | 1,880,685,962.88 |
| 非流动资产: | | | | |
| 长期股权投资 | 88,972,584.57 | 91,136,668.33 | 93,934,330.29 | 92,255,731.98 |
| 其他非流动金融资产 | 4,036,615.05 | 4,036,615.05 | 3,470,764 | 3,262,013.13 |
| 固定资产 | 1,450,187,865.53 | 1,492,727,114.86 | 1,530,910,409.24 | 1,571,232,514.66 |
| 在建工程 | 357,964,527.38 | 348,356,005.52 | 338,342,088.98 | 271,411,431.02 |
| 使用权资产 | 92,437,978.28 | 129,239,340.02 | 134,796,947.14 | 142,575,949.56 |
| 无形资产 | 144,947,184.48 | 146,059,504.21 | 148,189,896.17 | 149,043,139.57 |
| 商誉 | 118,769,811.89 | 118,769,811.89 | 118,769,811.89 | 118,769,811.89 |
| 长期待摊费用 | 5,831,466.62 | 6,259,715.3 | 6,673,434.32 | 7,070,555.24 |
| 其他非流动资产 | 192,482,256.95 | 180,652,747.92 | 206,977,190.53 | 232,252,129.44 |
| 非流动资产合计 | 2,455,630,290.75 | 2,517,237,523.1 | 2,582,064,872.56 | 2,587,873,276.49 |
| 资产总计 | 4,568,347,277.04 | 4,555,842,397.99 | 4,527,089,263.1 | 4,468,559,239.37 |
| 流动负债: | | | | |
| 短期借款 | 1,353,107,649.18 | 1,146,670,403.08 | 1,218,679,921.74 | 1,009,707,409.7 |
| 衍生金融负债 | 2,682,114.57 | 2,682,114.57 | 3,097,224.9 | 3,097,224.9 |
| 应付票据及应付账款 | 150,979,523.6 | 197,379,686.69 | 144,526,296.64 | 114,973,979.72 |
| 应付账款 | 150,979,523.6 | 197,379,686.69 | 144,526,296.64 | 114,973,979.72 |
| 合同负债 | 303,519,627.56 | 288,593,334.39 | 224,772,274.64 | 403,305,690.48 |
| 应付职工薪酬 | 97,716,633.14 | 88,640,829.64 | 74,091,214.81 | 58,352,851.14 |
| 应交税费 | 19,742,524.65 | 18,912,574.41 | 44,583,910.69 | 55,937,665.15 |
| 其他应付款合计 | 175,726,336.79 | 197,488,353.91 | 183,143,119.7 | 210,549,211.17 |
| 一年内到期的非流动负债 | 301,976,839.97 | 318,201,785.93 | 264,561,835.91 | 227,528,685.7 |
| 其他流动负债 | 6,361,516.78 | 34,464.07 | 562,953.63 | 379,500.01 |
| 流动负债合计 | 2,411,812,766.24 | 2,258,603,546.69 | 2,158,018,752.66 | 2,083,832,217.97 |
| 非流动负债: | | | | |
| 长期借款 | 977,580,389.08 | 948,030,389.08 | 948,763,657.8 | 960,763,657.8 |
| 应付债券 | 477,213,713.69 | 392,954,717.92 | - | - |
| 租赁负债 | 79,290,654.36 | 114,038,281.86 | 117,318,107.04 | 127,846,258.62 |
| 长期应付款 | 76,268,711.17 | 51,906,324.38 | 77,235,241.21 | 38,628,049.75 |
| 预计负债 | 1,233,323.09 | 1,034,990.88 | 1,228,134.56 | 1,529,301.9 |
| 递延收益 | 27,448,939.5 | 28,213,491.18 | 30,124,987.16 | 27,380,931.86 |
| 其他非流动负债 | 228,287,858.32 | 228,057,827.52 | 248,817,914.33 | 225,000,000 |
| 非流动负债合计 | 1,867,323,589.21 | 1,764,236,022.82 | 1,423,488,042.1 | 1,381,148,199.93 |
| 负债合计 | 4,279,136,355.45 | 4,022,839,569.51 | 3,581,506,794.76 | 3,464,980,417.9 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 399,600,000 | 399,600,000 | 399,600,000 | 399,600,000 |
| 资本公积 | 5,760,060,550.59 | 5,760,049,994.26 | 5,760,039,401.32 | 5,760,019,492.36 |
| 减:库存股 | 49,994,541.01 | 49,994,541.01 | 10,694,572.22 | - |
| 其他综合收益 | 3,694,968.17 | 4,454,583.67 | 5,083,841.36 | 5,038,733.13 |
| 未分配利润 | -6,006,545,925 | -5,764,602,337.39 | -5,392,928,818.71 | -5,346,587,738.72 |
| 归属于母公司股东权益合计 | 106,815,052.75 | 349,507,699.53 | 761,099,851.75 | 818,070,486.77 |
| 少数股东权益 | 182,395,868.84 | 183,495,128.95 | 184,482,616.59 | 185,508,334.7 |
| 股东权益合计 | 289,210,921.59 | 533,002,828.48 | 945,582,468.34 | 1,003,578,821.47 |
| 负债和股东权益合计 | 4,568,347,277.04 | 4,555,842,397.99 | 4,527,089,263.1 | 4,468,559,239.37 |
| 公告日期 | 2026-04-29 | 2026-03-25 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |